Cargando…
Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives
Good practices around model‐informed drug discovery and development (MID3) aim to improve the implementation, standardization, and acceptance of these approaches within drug development and regulatory review. A survey targeted to clinical pharmacology and pharmacometric colleagues across industry, t...
Autores principales: | Marshall, Scott, Madabushi, Rajanikanth, Manolis, Efthymios, Krudys, Kevin, Staab, Alexander, Dykstra, Kevin, Visser, Sandra A.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389350/ https://www.ncbi.nlm.nih.gov/pubmed/30411538 http://dx.doi.org/10.1002/psp4.12372 |
Ejemplares similares
-
Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making
por: Madabushi, Rajanikanth, et al.
Publicado: (2022) -
Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non‐orphan drugs approved by the FDA
por: Hsieh, Julie, et al.
Publicado: (2022) -
Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation
por: Marshall, SF, et al.
Publicado: (2016) -
A Holistic and Integrative Approach for Advancing Model‐Informed Drug Development
por: Madabushi, Rajanikanth, et al.
Publicado: (2019) -
Emerging Role of Organ‐on‐a‐Chip Technologies in Quantitative Clinical Pharmacology Evaluation
por: Isoherranen, Nina, et al.
Publicado: (2019)